These therapies include indirectly targeting MYC in combination with the PI3K pathway, mechanistic target of rapamycin (mTOR), or histone deacetylases (HDACs) for the treatment of T-cell acute lymphoblastic leukemia, pancreatic ductal adenocarcinoma, and osteosarcoma, respectively44–46. The gene discussed is MYC; the disease is osteosarcoma.